Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD),Journal of Neuroimmunology

当前位置： X-MOL 学术 › J. Neuroimmunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)
Journal of Neuroimmunology ( IF 2.9 ) Pub Date : 2020-11-01 , DOI: 10.1016/j.jneuroim.2020.577361
Young Nam Kwon ₁ , Boram Kim ₂ , Sohyun Ahn ₃ , Jaeyoung Seo ₄ , Sang Beom Kim ₅ , Sung Sang Yoon ₆ , Jung-Joon Sung ₇ , Youn Soo Choi ₈ , Sung-Min Kim ₇

Affiliation

Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea; Department of Neurology, The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Republic of Korea; Department of Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
Department of Neurology, Seoul National University College of Medicine, Neuroscience Research Institute, Seoul, Republic of Korea.
Department of Neurology, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea.
Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Department of Neurology, Kyung Hee University Hospital, Seoul, Republic of Korea.
Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea; Department of Neurology, Seoul National University College of Medicine, Neuroscience Research Institute, Seoul, Republic of Korea.
Department of Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.

BACKGROUND To evaluate the serum cytokine profiles in patients with myelin oligodendrocyte glycoproteins antibody associated disease (MOGAD), compared to those in neuromyelitis optica spectrum disorder with aquaporin-4 immunoglobulin G (APQ4-IgG+ NMOSD), multiple sclerosis (MS), and other inflammatory demyelinating diseases (IDDs). METHODS The level of interleukin (IL)-1β, IL-5, IL-6, IL-10, IL-12p70, IL-17A, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ in sera from 21 patients with MOGAD, 32 APQ4-IgG+ NMOSD, 24 MS, and 16 other IDDs were assessed. RESULTS In MOGAD patients, the levels of IL-1β and IL-12p70 were elevated compared to APQ4-IgG+ NMOSD. The level of IL-10 and the ratio of T helper (Th)-1/Th2-related cytokines were elevated in MOGAD patients compared to MS or other IDDs. In an intragroup analysis, the IL-1β was increased in acute stage of MOGAD, APQ4-IgG+ NMOSD, and also MS compared to their chronic stage counterpart. It was inversely correlated with time from acute attack to sampling in MOGAD (p < 0.001) and AQP4-IgG+ NMOSD (p = 0.001), but not in MS. Moreover, the IL-1β was most markedly upregulated in MOGAD sera sampled within 1 week from acute attack compared to those sampled after (p = 0.002). CONCLUSIONS The serum IL-1β can be elevated in the acute stage of patients with diverse IDDs including, MOGAD, APQ4-IgG+ NMOSD, and MS. This upregulation of serum IL-1β can be most markedly observed in the early acute stage of MOGAD patients. Further studies seem to be needed to determine the proper mechanism for the upregulation of serum IL-1β and also the role of IL-1β inhibition especially at the early acute stage of MOGAD.

中文翻译：

炎症性脱髓鞘疾病患者血清 IL-1β 水平：在 MOG 抗体相关疾病 (MOGAD) 的早期急性期显着上调

背景评估髓鞘少突胶质细胞糖蛋白抗体相关疾病 (MOGAD) 患者与具有水通道蛋白 4 免疫球蛋白 G (APQ4-IgG+ NMOSD)、多发性硬化症 (MS) 和其他炎症的视神经脊髓炎谱系障碍患者的血清细胞因子谱脱髓鞘疾病（IDD）。方法检测血清中白细胞介素（IL）-1β、IL-5、IL-6、IL-10、IL-12p70、IL-17A、肿瘤坏死因子（TNF）-α和干扰素（IFN）-γ的水平。评估了 21 名 MOGAD 患者、32 名 APQ4-IgG+ NMOSD、24 名 MS 和 16 名其他 IDD 患者。结果在 MOGAD 患者中，与 APQ4-IgG+ NMOSD 相比，IL-1β 和 IL-12p70 的水平升高。与 MS 或其他 IDD 相比，MOGAD 患者的 IL-10 水平和 T 辅助 (Th)-1/Th2 相关细胞因子的比率升高。在组内分析中，IL-1β 在 MOGAD、APQ4-IgG+ NMOSD 和 MS 的急性期与其慢性期对应物相比增加。在 MOGAD (p < 0.001) 和 AQP4-IgG+ NMOSD (p = 0.001) 中，它与从急性发作到采样的时间呈负相关，但在 MS 中则不然。此外，与急性发作后 1 周内采样的 MOGAD 血清相比，IL-1β 的上调最显着（p = 0.002）。结论血清 IL-1β 可在多种 IDD 患者的急性期升高，包括 MOGAD、APQ4-IgG+ NMOSD 和 MS。这种血清 IL-1β 的上调可以在 MOGAD 患者的早期急性期最明显地观察到。似乎需要进一步的研究来确定血清 IL-1β 上调的正确机制以及 IL-1β 抑制的作用，尤其是在 MOGAD 的早期急性期。

更新日期：2020-11-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11